# A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

> **NCT05372120** · PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ICP-192

## Key facts

- **NCT ID:** NCT05372120
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372120, "A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05372120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*